Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Crofelemer (Primary)
- Indications Diarrhoea
- Focus Adverse reactions
- Acronyms HALT-D
- 01 Feb 2017 Status changed from not yet recruiting to recruiting.
- 08 Nov 2016 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2016.
- 19 Sep 2016 Status changed from recruiting to not yet recruiting.